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The grant review system at the National Institutes of Health (NIH), the main mechanism by 
which NIH identifies research worthy of support, has been through a major overhaul. Scien-
tists who spearheaded the change say it is time to assess how the new system is working.There is no doubt that the grants 
system of the National Institutes of 
Health (NIH) is under strain. After a 
doubling of its budget to $27 billion 
from 1998 to 2003, NIH funding in the 
past three years has not kept up with 
inflation (see Figure 1). Researchers 
at all stages of their careers are frus-
trated by difficulties in having their 
grant applications approved, and 
some have even started pinning the 
blame on the NIH administration itself. 
In a recent editorial, which spurred a 
flurry of passionate responses from 
the research community, Journal of 
Clinical Investigation editor Andrew 
Marks charged NIH director Elias 
Zerhouni with irresponsibly funneling 
precious funds away from investiga-
tor-initiated research supported by 
traditional R01 grants.
But as that debate continues to 
fester, a number of scientists and 
 professional societies are focusing 
their attention on improving the sys-
tem of peer review for NIH grants. The 
NIH study sections, the functional 
units of grant review, have been reor-
ganized in a process that began over 
six years ago and was completed last 
year. Now the new structure needs to 
be evaluated for potential hitches. 
“Personally I think this is one of the 
most important issues at this time, 
when many people are not getting 
funded,” says Bruce Alberts, former 
president of the National Academy 
of Sciences and currently at the 
University of California, San Fran-
cisco. Alberts chaired the Panel on 
Scientific Boundaries for Review, 
an independent advisory group 
that recommended the new organi-
zation for NIH study sections. “The 
heart of our proposal was to create 
a structure that would be amenable 
to continuous oversight by scien-
tists,” he adds.Grant Review at a Glance
The Center for Scientific Review 
(CSR) at the NIH manages the review 
of most investigator-initiated appli-
cations, including R01s, fellowships, 
and small business applications. 
Individual NIH institutes and centers 
manage the review of applications in 
response to specific program initia-
tives, such as Requests for Applica-
tions (RFAs), multicenter clinical tri-
als, and so on.
Grant applications to be reviewed 
within CSR—comprising about 70% 
of all applications submitted to NIH—
are assigned to one of 23 so-called 
integrated review groups (IRGs), 
each consisting of a cluster of sci-
entifically related study sections. 
CSR then assigns applications to the 
appropriate study section within the 
IRG. Study sections meet independ-
ently three times a year near the NIH 
campus in Bethesda, Maryland to 
discuss and score applications.
After CSR completes its review of 
the application it sends a summary 
statement containing a score and, in 
some cases, a percentile ranking to 
the responsible institute or center. Cell 12Advisory councils then make fund-
ing recommendations based on the 
CSR evaluation, taking into consid-
eration the institute’s or center’s sci-
entific goals.
In 2000, NIH reviewed 44,000 
grant applications of which 32,000 
were handled by CSR. But by 2005, 
the total number had grown to 73,000 
with 52,000 of these being handled 
by CSR. As more investigators sub-
mit R01 grants (R01 applications 
from new investigators jumped from 
9,595 in 2001 to 18,047 in 2004) and 
each investigator submits, on aver-
age, more grant applications, the 
number of R01s awarded by NIH has 
gone down slightly. These factors 
combined have sent success rates 
for grant applications plummeting 
(see Figure 2).
Reorganizing the Study Sections
In 2000, the Panel on Scientific 
Boundaries for Review recommended 
a new organizational structure for 
IRGs, which would more accurately 
reflect the types of research appli-
cations that NIH receives. “The first 
study sections were established in Figure 1. NIH Budget for Fiscal Years 1995 to 2007
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Figure 2. Success Rates for All Competing NIH Grants for Fiscal Years 1995 to 2005 
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despite the fact that science has 
changed dramatically. Reorganiza-
tion was one option to address this 
issue,” says Anthony Scarpa, who 
became CSR director in July 2005. 
Another issue the panel grappled 
with was that some of the most cut-
ting edge research was assigned to 
too few study sections causing the 
best science to compete with itself, 
whereas relatively low impact work 
had little or no competition. The goal 
of the new IRG structure was to even 
out the playing field.
The panel recommended a new set 
of IRGs and invited public comment 
and suggestions from the scientific 
community. Then groups of scien-
tists with expertise in different areas 
decided what types of study sections 
should populate each IRG. Under the 
new structure, basic science research 
that applies to physiological prob-
lems was assigned to study sections 
with a broader focus than in the past, 
enabling review of grants contain-
ing both basic and disease-oriented 
research. “It was an important but 
difficult undertaking,” says Keith R. 
Yamamoto, vice dean for research 
at the School of Medicine, Univer-
sity of California, San Francisco, who 
chaired the CSR advisory committee. 
“It was like turning a huge ship.”
Is the New System Working?
The final study sections were put in 
place last year, prompting former 824 Cell 125, June 2, 2006 ©2006 Elseviepanel members to urge NIH to evalu-
ate the changes. “Part of the reason 
for the reorganization was that we 
envisioned that a relatively small 
group of experts could keep the 
system working effectively,” says 
Alberts. The plan, says Alberts, was 
that a group of about 8 to 10 sci-
entists could oversee each IRG, by 
sitting in on study section meetings 
as ad hoc reviewers, to determine 
if adjustments to the new structure 
were needed. “It is more important 
to have this kind of oversight in place 
at the early stages [of the reorganiza-
tion],” he says.
In particular, the panel suggested 
that the scientific expertise in each 
study section be monitored to ensure 
that it matches the scientific areas 
covered by the grant applications. 
“We finalized the structure about 2 to 
3 years ago. But fields are changing 
in a big hurry. We need to make sure 
that each IRG covers its respective 
field and that the number and focus 
of the study sections is appropriate,” 
says Peter H. von Hippel, a chemist 
and molecular biologist at the Univer-
sity of Oregon and former member 
of the panel. Says Yamamoto, “No 
matter how refined a process is, even 
with thoughtful input from thousands 
of people, the chances of doing it per-
fectly the first time are next to zero. 
CSR needs to be alert to problems 
and quickly react to them.”
Another concern is that “in some 
cases, basic science expertise is not r Inc.well-represented, so basic science 
grants are not getting expert review,” 
says Heidi Hamm, a pharmacolo-
gist at Vanderbilt University Medical 
Center who is president-elect of the 
American Society of Biochemistry 
and Molecular Biology (ASBMB). 
“With the reorganization something 
like 5 to 6 basic biochemistry study 
sections are gone, and thus grants in 
a wide range of expertise are being 
funneled to just a few, much larger, 
study sections.” Others echo the 
concern. “One of the big concerns 
before the reorganization was that 
translational science was not getting 
a fair review. Now we may have gone 
to the other extreme. The empha-
sis may have now swung to trans-
lational research to the detriment 
of outstanding basic science,” says 
Judith Bond of Penn State Univer-
sity, ASBMB’s current president.
Calling All Reviewers
Each year, thousands of reviewers 
are asked by CSR to serve on study 
sections for 1 to 3 months a year. 
Currently, one third of reviewers are 
permanent members who serve a 
four-year term on a particular study 
section; the rest are ad hoc or tem-
porary members. The recent increase 
in grant applications and lower suc-
cess rates have contributed to 
what Scarpa refers to as “reviewers 
fatigue.” According to Scarpa, there 
is a reluctance not only to participate 
on study sections but also to take on 
the usual load of a dozen or so grants 
per review cycle. “The review system 
is under significant stress. When you 
need 18,000 reviewers a year, you 
sometimes have limited choice as to 
who to ask,” he says. “The real crisis 
is not being able to always have the 
best reviewers.”
A number of professional societies 
are helping CSR to address this issue. 
The American Society for Cell Biol-
ogy is reaching out to its members at 
society meetings to encourage them 
to serve on study sections. “It is one 
of the major problems we are focus-
ing on,” says spokesman Kevin Wil-
son. The ASBMB took a more proac-
tive approach by conducting a formal 
survey of its membership. They found 
that 70% of associate and full profes-
sors are willing to participate in study 
sections. “In the past there was an 
unspoken rule that if you have served 
a four-year term on a study section 
as part of your professional require-
ment then you had done your job. 
We are trying to change that,” says 
Hamm. ASBMB has provided a list 
of 700 individuals that NIH can tap 
as potential reviewers, provided that 
they meet all the necessary require-
ments. “[Our members] are very 
engaged in wanting the system to get 
better,” she adds.
Some are concerned about the 
increase in the number of junior fac-
ulty on study sections. In May 1998, 
about 1% of the permanent review-
ers were assistant professors. By 
May 2005, that number has grown 
to about 7.5% percent. “[Assistant 
professors] are inexperienced and 
may tend to address technical issues 
rather than the real important prob-
lems. Also it’s not fair to them to sit 
on study sections as it is an onerous 
task,” says Hamm. Suzanne Pfeffer, 
chair of the department of biochem-
istry at Stanford University School 
of Medicine, agrees. “I do advise my 
junior faculty not to serve on a formal 
study section mostly because of the 
amount of time required. It is a very 
big responsibility,” she says. “I agree 
it can be a useful learning experience, 
but I advise them to focus on their 
own work until they have tenure.”
Although scientific societies are 
doing their part to urge their constit-
uents to participate, CSR is imple-
menting some practical changes 
to make the review system more 
accessible to busy senior investi-
gators. For example, the center is 
experimenting with asynchronous 
Internet-assisted discussion in 
secure chat rooms, to allow review-
ers to meet and comment on grant 
applications without having to fly to the NIH campus for formal meetings. 
CSR is also considering making R01 
grant applications shorter than the 
current 25 dense pages with unlim-
ited appendices. “We have talked 
to various groups about this and 
some are in favor of the idea. Each 
reviewer would be able to read more 
grants and we would need fewer 
people,” says Scarpa.
Young Investigators
If the funding situation is frustrat-
ing for established scientists, junior 
faculty are feeling the pinch. Grants 
from new investigators consistently 
fare worse than those from experi-
enced investigators—for example, 
in 2004, 14.6% of R01 applications 
from new investigators scored in 
the top 20th percentile compared to 
17.7% from experienced investiga-
tors. In addition, more new investiga-
tor applications (47.8% compared to 
40.6% for established investigators) 
were “streamlined,” a process in 
which the bottom 50% of applica-
tions to a study section are not dis-
cussed at the review meeting and are 
not scored.
“There has always been great 
concern about facilitating careers of 
young scientists. These times when 
funding is tighter, there should be even 
more concern,” says Yamamoto. In 
January of this year, NIH announced 
its Pathway to Independence Award 
Program. Starting in the fall of 2006, 
NIH will issue between 150 and 200 
awards to provide support during the 
transition between a postdoctoral 
fellowship and independent investi-
gator position. “What NIH has done 
sends a positive message,” says 
Yamamoto.
R01 applications contain a box to 
be filled out by new investigators, 
which alerts reviewers to be more 
lenient. “Reviewers are instructed 
to put more emphasis on training, Cell 125environment and innovation when 
assessing applications from new 
investigators and CSR monitors 
these reviews,” says Scarpa. But 
others say that more could be done. 
“CSR should make two lists of initial 
priority scores, listing young inves-
tigators separately from established 
ones,” says von Hippel. Study sec-
tions would have to discuss and pri-
oritize the top applications from new 
investigators, regardless of how they 
are initially ranked in comparison to 
those of established investigators, 
thereby reducing the number of new 
investigator applications that are 
streamlined.
Scarpa has adopted other meas-
ures to speed up the review of 
grants submitted by young inves-
tigators. In a pilot study of 6,000 
new investigators, CSR scheduled 
study section meetings earlier than 
usual, provided applicants with their 
scores, critiques, and panel discus-
sion summaries within a week of the 
study section meeting, and extended 
resubmission deadlines by 3 weeks. 
“Normally if you submit a grant in 
February, by the time you get com-
ments back and make revisions, you 
have to wait until November to resub-
mit the application. Our goal was to 
allow resubmission of the grant at 
the next cycle,” says Scarpa. Once 
the new system is evaluated, CSR 
plans to extend these changes to all 
investigators.
The funding situation is unlikely to 
improve anytime soon but optimizing 
the NIH grant review system might 
relieve some of the strain research-
ers are feeling. “The peer review sys-
tem looks like it is in crisis because of 
the funding situation. If money were 
plentiful, it would mask any problems 
with it,” says Yamamoto. “A solution 
can be achieved by providing more 
money, but when this is not possible 
you need to fix other problems.”, June 2, 2006 ©2006 Elsevier Inc. 825
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